Dengue Immunization starts in Brazil with a pilot plan in three small municipalities in Rio de Janeiro. The Government launched this initiative on Saturday, using the first national vaccine against the virus, developed entirely in the country.
Initial Launch Details
The program focuses on small localities to evaluate effectiveness and logistics before a possible expansion. The main goal is the population of 15 to 29 years, a high-risk group due to exposure to the Aedes aegypti mosquito, the main transmitter of dengue. Authorities hope to collect key data for a massive national campaign.
Context of Dengue Immunization in Brazil
Brazil faces recurring dengue epidemics. In 2024, the country registered over 6 million cases and nearly 5,000 deaths, according to data from the Ministry of Health. This dengue immunization represents a milestone, as the vaccine, called Butantan-DV, was created by the Butantan Institute after years of research with viral vector technology.
Background and Development of the Vaccine
The national vaccine emerged as a response to the 2019 crisis, when Brazil led global cases. Phase 3 clinical trials demonstrated 80% effectiveness against severe forms in young adults. Dr. Esper Kallás, an expert from the Butantan Institute, highlighted: “This dengue immunization could reduce hospitalizations by 60% in the target age group”.
- First doses administered in municipalities with a history of intense outbreaks.
- Monitoring of secondary effects and immune response for six months.
- Possible approval for general use if results are positive.
Regional Impact and Lessons for Latin America
In Latin America, dengue affects 400 million annually, with peaks in the Dominican Republic and Caribbean neighbors. Brazil, with this dengue immunization, could serve as a model. Countries like Mexico and Argentina are already negotiating access to the formula. OPS statistics indicate that vaccines reduce mortality by 90% in endemic areas.
The pilot plan advances with strict supervision. Experts agree that an effective dengue immunization depends on wide coverage and combination with vector control. Brazil positions its national vaccine as a key tool against future epidemic waves, potentially benefiting the entire region.
